
Sandra Hanna
Advertisement
Articles by Sandra Hanna


Tbo-filgrastim (Granix) is FDA approved to reduce the duration of severe neutropenia in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy with significant evidence of febrile neutropenia.


Bloxiverz, manufactured by Éclat Pharmaceuticals, is the first and only FDA-approved neostigmine methylsulfate injection.
Advertisement
Latest Updated Articles
Neostigmine Methylsulfate Injection (Bloxiverz)Published: November 15th 2013 | Updated:
Dolutegravir (Tivicay)Published: January 14th 2014 | Updated:
TBO-Filgrastim (Granix)Published: March 12th 2014 | Updated:
Sofosbuvir (Sovaldi)Published: July 15th 2014 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Earlier Menopause, Reduced Cardiac Function Potentially Linked With Negative Impacts on Brain Health
2
A Multifaceted Approach to Navigating Career Transitions in Pharmacy
3
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
4
Menopause Care Varies by Provider, Highlighting Need for Standardized Education
5





